Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow IMCR
Immunocore Holdings PLC Sponsored ADR (IMCR) Piotroski F-score
Immunocore Holdings PLC Sponsored ADR's Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | (1.00) |
| FY2024 | 4 | (2.00) |
| FY2023 | 6 | 1.00 |
| FY2022 | 5 | 2.00 |
| FY2021 | 3 | (1.00) |
| FY2020 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (3.42%) | (6.36%) | Fail | 0 |
| Positive operating cash flow | (10.71m) | 26.06m | Fail | 0 |
| Rising return on assets | (3.42%) | (6.36%) | Pass | 1 |
| Cash flow above net income | 24.80m | 77.15m | Pass | 1 |
| Falling long-term leverage | 0.38 | 0.49 | Pass | 1 |
| Rising current ratio | 4.04 | 4.38 | Fail | 0 |
| No new shares issued | 50,346,000 | 49,991,000 | Fail | 0 |
| Rising gross margin | 98.73% | 99.12% | Fail | 0 |
| Rising asset turnover | 0.39 | 0.39 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ANAB AnaptysBio, Inc. compare | 5 |
| RARE Ultragenyx Pharmaceutical Inc. compare | 5 |
| QURE uniQure N.V. compare | 5 |
| NTLA Intellia Therapeutics, Inc. compare | 4 |
| IMCR Immunocore Holdings PLC Sponsored ADR | 3 |
| ABSI Absci Corporation compare | 3 |
| MAZE Maze Therapeutics, Inc. compare | — |
| KRSA Korsana Biosciences, Inc. compare | — |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover